Stephens Inc. AR raised its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,683 shares of the biopharmaceutical company’s stock after acquiring an additional 439 shares during the quarter. Stephens Inc. AR’s holdings in Alexion Pharmaceuticals were worth $813,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALXN. BlackRock Inc. increased its position in Alexion Pharmaceuticals by 2,689.8% in the 1st quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after acquiring an additional 17,960,356 shares in the last quarter. Bank of Montreal Can grew its position in shares of Alexion Pharmaceuticals by 628.8% during the 2nd quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock worth $173,174,000 after buying an additional 1,228,025 shares during the period. Bessemer Group Inc. grew its position in shares of Alexion Pharmaceuticals by 1,949,640.5% during the 2nd quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock worth $87,772,000 after buying an additional 721,367 shares during the period. State Street Corp grew its position in shares of Alexion Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after buying an additional 718,756 shares during the period. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Alexion Pharmaceuticals during the 1st quarter worth approximately $65,219,000. Hedge funds and other institutional investors own 94.17% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 146.69 on Monday. The stock has a 50 day moving average of $138.83 and a 200-day moving average of $124.75. The company has a market cap of $32.74 billion, a price-to-earnings ratio of 63.61 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.13 earnings per share. On average, analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.62 EPS for the current year.

In other news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders sold 17,070 shares of company stock valued at $2,416,869 in the last quarter. Corporate insiders own 4.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Stephens Inc. AR Boosts Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/18/stephens-inc-ar-boosts-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Several brokerages have recently commented on ALXN. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $161.00 price target for the company. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets reiterated an “outperform” rating and set a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Deutsche Bank AG reiterated a “buy” rating and set a $158.00 price target (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Five research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $157.13.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.